Abbott filed to sell $20 billion of senior notes to help finance its planned $23 billion acquisition of Exact Sciences. The multi-tranche offering spans floating-rate and fixed‑rate maturities across 2029–2066, with major banks underwriting the deal. Abbott said proceeds will also repay certain indebtedness of Exact and support general corporate purposes. Exact Sciences shareholders previously approved the acquisition; Abbott expects the takeover to close in Q2 2026. The debt raise signals Abbott’s commitment to close the transaction and reflects confidence in the combined diagnostics and platform revenue streams. Market commentators noted the financing increases Abbott’s leverage but argued strategic long-term synergies in cancer diagnostics and point-of-care testing could justify the capital structure if integration proceeds smoothly.